<DOC>
	<DOCNO>NCT02283814</DOCNO>
	<brief_summary>Single centre , open-label , multiple dos , one-sequence design study two parallel group healthy volunteer</brief_summary>
	<brief_title>A Open-label , Drug Interaction Study Between Eslicarbazepine Acetate Topiramate</brief_title>
	<detailed_description>Single centre , open-label , multiple dos , one-sequence design study two parallel group healthy volunteer : Group A : Pre-treatment ESL , treatment ESL ascend dos Topamax ( TPM ) last phase ; Group B : Pre-treatment TPM , treatment TPM ascend dos ESL last phase</detailed_description>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Availability volunteer entire study period willingness adhere protocol requirement evidence informed consent form ( ICF ) duly read , sign date volunteer Male age least 18 year old 45 year body mass índex ( BMI ) great equal 19 30 kg/m Clinical laboratory value within laboratory 's state normal range ; f within range , must without clinical significance ( laboratory test present section 6.1.1.3 ) Healthy accord medical history , laboratory result physical Light , non exsmokers . A light smoker define someone smoke 1 0 cigarette less per day , exsmoker define someone completely stop smoke least 1 2 month day 1 study Significant history hypersensitivity topiramate , eslicarbazepine , oxcarbazepine , carbamazepine relate product ( include excipients formulation ) wel l severe hypersensitivity reaction ( like angioedema ) drug Presence significant gastrointestinal , l iver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect History significant gastrointestinal , liver r kidney disease , r surgery may affect drug bioavailability , include limited cholecystectomy Presence significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , endocrine , immunologic dermatologic isease Presence f significant heart disease r disorder accord ECG Presence history significant central nervous system disorder l ike convulsion depression Presence r history f significant ocular disease Presence history severe hepatic impairment Presence history renal insufficiency ( serum creatinine level great 135 μmol/L ) History presence acidosis Use valproic acid previous 7 day prior Day 1 study . Maintenance therapy drug , significant history drug dependency alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) Any clinically significant illness previous 28 day day 1 study Use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin rifampin ) , previous 28 day Day 1 study Participation another clinical trial donation 50 mL blood previous 28 day day 1 study Donation 500 mL blood ( Canadian B lood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study Positive urine screen drug abuse ( drug list present section 6.1.1.4 ) . Positive result HIV , HBsAg antiHCV test</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>